André Ostachkov
Directeur/Membre du Conseil chez DoseVue NV
Profil
André Ostachkov is currently a Director at Graftys SA, DoseVue NV, Apaxen SA, Home EOS NV, and a Principal at Innovation Fund (BE).
He previously worked as a Non-Executive Director at TheraVet SA. Mr. Ostachkov received an undergraduate degree from Escuela Superior de Administración y Dirección de Empresas in 2001 and another undergraduate degree from The Louvain School of Management.
Postes actifs de André Ostachkov
| Sociétés | Poste | Début |
|---|---|---|
Innovation Fund (BE)
 Innovation Fund (BE) Investment ManagersFinance Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium. | Private Equity Investor | 01/07/2018 |
Apaxen SA
 Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | Directeur/Membre du Conseil | 29/07/2019 |
DoseVue NV
 DoseVue NV Medical SpecialtiesHealth Technology DoseVue NV is developing innovative technologies for convenient and accurate in-vivo dosimetry. It offers DoseWire Series 100 & DoseWire Series 200. The company was founded by Emiliano D Agostino in March 2013 and is headquartered in Turnhout, Belgium. | Directeur/Membre du Conseil | - |
Graftys SA
 Graftys SA Medical SpecialtiesHealth Technology Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France. | Directeur/Membre du Conseil | - |
Home EOS NV
 Home EOS NV Engineering & ConstructionIndustrial Services Home EOS NV is a company based in Farciennes, Belgium. Home EOS specializes in providing a serene and healthy living environment with effective and ecological acoustic insulation. The Belgian company was founded in 2014 and Pierre P. de Kettenis de Hollaeken has been the CEO of the company since 2016. | Directeur/Membre du Conseil | 25/03/2021 |
Anciens postes connus de André Ostachkov
| Sociétés | Poste | Fin |
|---|---|---|
| THERAVET SA | Directeur/Membre du Conseil | - |
Formation de André Ostachkov
| The Louvain School of Management | Undergraduate Degree |
| Escuela Superior de Administración y Dirección de Empresas | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| THERAVET SA | Commercial Services |
| Entreprise privées | 5 |
|---|---|
Innovation Fund (BE)
Innovation Fund (BE) Investment ManagersFinance Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium. | Finance |
Apaxen SA
Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | Health Technology |
DoseVue NV
DoseVue NV Medical SpecialtiesHealth Technology DoseVue NV is developing innovative technologies for convenient and accurate in-vivo dosimetry. It offers DoseWire Series 100 & DoseWire Series 200. The company was founded by Emiliano D Agostino in March 2013 and is headquartered in Turnhout, Belgium. | Health Technology |
Graftys SA
Graftys SA Medical SpecialtiesHealth Technology Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France. | Health Technology |
Home EOS NV
Home EOS NV Engineering & ConstructionIndustrial Services Home EOS NV is a company based in Farciennes, Belgium. Home EOS specializes in providing a serene and healthy living environment with effective and ecological acoustic insulation. The Belgian company was founded in 2014 and Pierre P. de Kettenis de Hollaeken has been the CEO of the company since 2016. | Industrial Services |
